SEARCH · PubMed Health
Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.
Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.
NEWCHEM, an artificial intelligence system for the control of cancer cell growth, is described. This system takes into account the most recent advances in molecular and cellular biology and in cell-drug interaction, and aims to develop optimal strategies for the selective control of cancer cell through qualitative reasoning from first principles at cellular level.
This article presents a further description on the background, significance, and structure characteristics of Quantitative Medicine Simulation and Operation by Computer (QMSOC). Also some basic operators were recommended for calculations of biomedical events such as estimation of substance concentrations, exploration of etiology, evaluation of biomedical effects, etc. At last some differences of QMSOC from other artificial intelligent systems in the medical field were discussed.
Two procedures for predicting the carcinogenicity of chemicals are described. One of these (CASE) is a self-learning artificial intelligence system that automatically recognizes activating and/or deactivating structural subunits of candidate chemicals and uses this to determine the probability that the test chemical is or is not a carcinogen. If the chemical is predicted to be carcinogen, CASE also projects its probable potency. The second procedure (CPBS) uses Bayesian decision theory to predict the potential carcinogenicity of chemicals based upon the results of batteries of short-term assays. CPBS is useful even if the test results are mixed (i.e. both positive and negative responses are obtained in different genotoxic assays). CPBS can also be used to identify highly predictive as well as cost-effective batteries of assays. For illustrative purposes the ability of CASE and CPBS to predict the carcinogenicity of a carcinogenic and a non-carcinogenic polycyclic aromatic hydrocarbon is shown. The potential for using the two methods in tandem to increase reliability and decrease cost is presented.
Recently Goldring et al. [Mutation Res., 187 (1987) 67-77] reported the synthesis and purification of a series of nitro-substituted cyclopenta-fused polycyclic aromatic hydrocarbons. On the basis of expected charge distributions, these chemicals were predicted to be potent mutagens and, yet, contrary to expectation, they were found to be only weakly mutagenic for Salmonella. In their discussion, the authors suggest that application of CASE, an artificial intelligence system recently developed in these laboratories, would also not predict the low mutagenicity of this group of chemicals. In the present report, it is shown that CASE, in fact, correctly predicts the low mutagenicity of nitro-substituted cyclopenta-fused polycyclic aromatic hydrocarbons.
Devices constructed for potential use as invasive bioprobes incorporate a selective receiving site for molecular or ionic recognition, and a transducer which is capable of translating a perturbation of physical chemistry of the determinant-site reaction (interaction) into a usable signal. Four types are envisioned--implants for general hospital use, transient-use probes to replace classical blood tests, short-term implantable probes and the long-term variety. Performance criteria are selectivity, sensitivity, fast response, site-reversible, small, rugged, inexpensive, biocompatible, calibratible, facile use by non-expert personnel and ease of telemetry. These demands, not surprisingly, create enormous challenges to the sensor specialist. With respect to biocompatibility the sensor must not be involved in infection, clot formation or antigenic response, and, furthermore, protein adsorption, etc., which can affect the sensor response should be avoided. Calibration remains a problem of monumental proportions. Many devices drift from calibrated levels even in in vitro experiments, let alone in the implanted milieu. One solution has been to carry out on-line switching between patient blood and standard solutions. However, this type of approach leaves a lot to be desired with respect to portability. Another method which is attracting increasing attention is the chemometric or artificial intelligence system involving compensation by multi-sensor array configurations. Sensitivity and limit-of-detection have attracted little research due to the overwhelming nature of other difficulties. In the present paper we evaluate a number of these technical problems and discuss the architecture of devices that are currently available. Finally, some thoughts as to priorities for re-directing sensor research in the bioprobe area are presented.
Alzheimer's disease (AD) is characterized by region- and patient-specific molecular heterogeneity, which hinders therapeutic design. In this study, we introduce PRISM-ML (PRecision-medicine using Interpretable Systems and Multiomics with Machine Learning), an open-source integrated analysis pipeline that combines interpretable machine learning with systems biology and electronic health records data mining to elucidate the molecular diversity of AD and predict promising drug repurposing opportunities. First, we integrated and harmonized transcriptomic (bulk RNA-seq) and genomic (genome-wide association study) data from 2105 brain samples, each with matched data from the same individual (1363 AD patients, 742 controls; 9 tissues), sourced from three independent studies. Random forest classifiers with SHapley Additive exPlanations identified patient-specific biomarkers; unsupervised clustering resolved 36 molecularly distinct subtissues (defined as clusters of samples within a brain tissue that share a specific expression pattern); and gene-gene coexpression networks prioritized 262 high-centrality bottleneck genes as putative regulators of dysregulated pathways. Next, knowledge graph-based drug repurposing predicted six Food and Drug Administration (FDA)-approved drugs that simultaneously target multiple bottleneck genes and multiple AD-relevant pathways. Notably, in a large US de-identified insurance-claims database (n = 364 733), exposure to promethazine, one of the candidate drugs, was associated with a 57%-62% lower incidence of AD versus an active antihistamine comparator (adjusted hazard ratio 0.38; inverse-probability weighted 0.43; both P < .001), providing real-world support for its repurposing potential. In summary, PRISM-ML, as an explainable multiomics analysis pipeline, is readily transferable to other complex diseases, advancing precision medicine.
There was agreement between the experimental results, obtained in the course of the Second UKEMS Collaborative Study, for the mutagenicity in Salmonella typhimurium of benzidine, 4,4"-diaminoterphenyl, 4-dimethylaminoazobenzene and 4-cyanodimethylaniline and the mutagenicity predicted by CASE (Computer Automated Structure Evaluation), a recently developed artificial intelligence system.
By studying all coronary heart attacks presenting within defined communities it should be possible to avoid the distortions and omissions inherent in hospital-based case series. In practice the technique presents several problems. Measures of frequency and outcome are very sensitive to the diagnostic criteria used. Data of varying quality are mixed and specific attack rates can be calculated only for items for which the census provides a denominator. Patients presenting to different medical services have different outcomes, but probably less because of treatment than because the severity of the attack affects behaviour in it. Despite these problems, some such intelligence system is of value in any comprehensive strategy for coronary heart disease.
An artificial intelligence system, NEWCHEM, for the development of new oncology therapies is described. This system takes into account the most recent advances in molecular and cellular biology and in cell-drug interaction, and aims to guide experimentation in the design of new optimal protocols. Further work is being carried out, aimed to embody in the system all the basic knowledge of biology, physiopathology and pharmacology, to reason qualitatively from first principles so as to be able to suggest cancer therapies.
Computers assist oncology nurses in their roles as "care integrators" and caregivers. Computers assist nurses in their care integrator role by supporting communication with ancillary departments and by aiding in the collection, organization, and storage of data. Computers helps nurses in their role as caregivers through automated care planning, discharge planning, and patient monitoring and by tracking patients' educational, therapeutic, comfort, or other needs. Using computers, nurses can document their assessments and interventions and patient outcomes while receiving cues and reminders about policies, procedures, and standards of care. In the future, oncology nurses can expect to see computer technology in more hospitals and a host of new developments, such as more intelligent systems, nursing and medical knowledge on-line, documentation at the bedside, and use of patient data bases in education and research.
There is a great deal we do not know about the safety of pharmaceutical agents, especially regarding their safe use in the workplace. Economic and scientific imperatives can lead to a new drug's approval and marketing even though testing is limited; therefore, much of the knowledge about drug toxicities must be developed in the postapproval period, through pharmacoepidemiologic methods. The system of epidemiologic intelligence depends on spontaneous, voluntary reports of adverse drug reactions and, as applied to the work force, it is fraught with problems of ascertainment, accountability, and application. Structured epidemiologic studies of these issues have been difficult to perform because of high costs, long time frames, and methodologic problems and biases. Nevertheless, large automated data bases, with the right input, hold great promise for making it easier to accumulate and analyze the data necessary for monitoring drug safety in the workplace.
Explore the source record for details and available documents.
The proliferation of monitors and alarms in the operating room may lead to increased confusion and misdiagnosis unless the information provided is better organized. Intelligent alarm systems are being developed to organize these alarms, on the assumption that they will shorten the time anesthesiologists need to detect and correct faults. This study compared the human response time (the time between the sounding of an alarm and the resolution of a fault) when anesthesiologists used a conventional alarm system and when they used an intelligent alarm system. In a simulated operating room environment, we asked 20 anesthesiologists to resolve seven breathing circuit faults as quickly as possible. Human response time was 62% faster, decreasing from 45 to 17 s, when the intelligent alarm system was used. The standard deviations in response time were only half as large for the intelligent alarm system. It appears that the computer-based neural network in the intelligent alarm system diagnosed faults more rapidly and consistently than did the anesthesiologists. This study indicates that breathing circuit faults may be more rapidly corrected when the anesthesiologist is guided by intelligent alarms.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
These experiments were carried out to assess how accurately the gains and compression ratios in a two-channel compression system needed to be set. We used as a research tool a laboratory version of a two-channel full-dynamic-range compression system. The system was initially adjusted to suit each hearing-impaired subject according to the manufacturer's recommendations. Then, further adjustments were made to ensure that speech stimuli were both audible and comfortable over a wide range of sound levels. Finally, the settings of the gains and compression ratios were systematically varied from the adjusted values and the effects of this on the intelligibility of speech in quiet and in noise (12-talker babble, levels of 65 and 75 dB SPL) were measured. The results indicated that speech reception thresholds (SRTs) in quiet were significantly adversely affected by decreases in low-level gain. However, SRTs in noise were relatively unaffected by changes in low-level gain. An exception occurred at the higher noise level used, where increases in the low-level gains (with corresponding increases in compression ratios) had a significant adverse effect on the SRTs. It is concluded that, provided excessive low-level gains (associated with high compression ratios) are avoided, the main criteria for fitting such a system should be listening comfort (i.e. achieving an acceptable tonal balance, and avoiding uncomfortably loud sounds) and an appropriate value of the threshold for detecting speech in quiet (which should be a little below 50 dB SPL).
Innovations in retinal imaging technologies and growing evidence from retinal imaging of systemic and neurodegenerative diseases have begun to explore the utility of retinal imaging in diagnosing these conditions. Since the retina shares embryological origins with the central nervous system and reflects systemic microvascular characteristics, it is well positioned for noninvasive observation of patients' systemic and neural health. Moreover, accessibility of retinal imaging has improved with the increasing number of ophthalmology clinics. Rapid improvements in various deep learning (DL) tools have also catalyzed the automation of retinal imaging analysis. Systems that utilize DL for retinal imaging are being developed to assist with disease recognition, clinical judgment, and prognostic assessment of systemic health. Various imaging modalities are being integrated with existing genomic and clinical data to estimate an individual's predisposition to certain conditions. Contrary to many existing reviews, the objective of this review is to synthesize the most recent clinical and technological evidence on DL-based diagnostic systems for retinal imaging, with a focus on how different network architectures and their combinations have been developed, validated, and applied across systemic disease detection and prediction. Specifically, this review examines the datasets, model validation approaches, and automated diagnostic systems reported in recent literature. It discusses the extent to which these advancements address existing barriers toward real-time diagnostic application across clinical disciplines. Integrating retinal imaging with DL is an innovative and promising approach to precision medicine and health risk reduction.
Explore the source record for details and available documents.